Court Sets Oct. 7 Deadline for FDA Mifepristone Review

FDA owes a federal court an update by October 7 on a mifepristone safety review the agency has conducted largely out of public view for more than a year. The deadline comes from an April 7, 2026 ruling in Louisiana v. FDA, in which a federal judge paused the state's challenge to the drug's telehealth and mail-order dispensing rule rather than decide it outright — on the condition that FDA report back on its own review within six months. That report is due this week, and it is the first real window regulatory and legal observers will get into how far the review has actually progressed.

A pause, not a resolution

Louisiana's suit, filed in October 2025, asks the court to strike down the 2023 REMS modification that allowed mifepristone to be prescribed via telehealth and dispensed by mail — a change that significantly widened access to medication abortion nationally. Rather than rule on that request in April, Judge Joseph granted the government's motion to pause the case while FDA's own safety review runs its course, reasoning that the agency's review could moot or reshape the legal questions in front of him. That is a meaningful procedural choice, not a neutral one: pausing litigation rather than deciding it keeps the 2023 rule, and the access it enables, in effect for now. But the same ruling found Louisiana has standing to bring the claim at all and is likely to succeed in arguing the REMS change was adopted without adequate legal process — a finding that puts real weight behind the state's position if and when the case resumes.

What FDA's review has said publicly, so far

FDA's REMS review was announced jointly by HHS Secretary Kennedy and then-Commissioner Makary in September 2025, framed as a response to a letter from 22 Republican state attorneys general citing studies the officials said raised new safety questions about mifepristone as currently administered. The announcement characterized the review as examining whether REMS modifications — potentially including a return to in-person dispensing requirements — are warranted. Beyond that initial framing and periodic public statements from Makary describing the review as ongoing, FDA has not published a public timeline, interim findings, or methodology for the study. That opacity is the specific gap October 7's status report is meant to address, at least in part: Judge Joseph's order asks for the review's process and any updated completion estimate, not a final conclusion, which the report may or may not supply in useful detail.

Why a REMS review, not a new approval, is the mechanism

• A REMS is a risk-management framework FDA can attach to an approved drug's labeling and distribution — it does not require withdrawing or re-approving the product to tighten or loosen it, which is why this dispute runs through an internal agency review rather than a new application.
• The 2023 change at issue removed the requirement that mifepristone be dispensed in person by a certified prescriber, among other modifications, enabling telehealth prescribing and mail-order pharmacy and retail-pharmacy dispensing that the drug's manufacturers and many clinicians say expanded access without new safety signals.
• Mifepristone remains one of the most litigated drugs in FDA's portfolio; this REMS review and the Louisiana case run alongside separate, ongoing litigation over the drug in other jurisdictions, which the October 7 report does not resolve.
• For sponsors and RA professionals generally, the case is a live example of how a REMS modification — typically a routine, low-visibility regulatory action — can become the central legal battleground for a product, with a federal court effectively setting the agency's own reporting cadence.

What the report does not do is end the case. Judge Joseph's ruling anticipated exactly this moment without committing to an outcome: the government gets a checkpoint, not a verdict, and the judge retains the option to lift the pause and rule on the merits — where his own preliminary read already favors Louisiana's standing and likely success — if the review's reported status does not satisfy him that FDA is moving with what he called “deliberate speed.” Regulatory News will follow the filing once it is public and FDA's and the court's next steps.

Frequently asked questions

What deadline is this, exactly?

In Louisiana v. FDA (W.D. Louisiana), Judge David C. Joseph ruled on April 7, 2026 to pause Louisiana's lawsuit challenging FDA's 2023 telehealth/mail-order dispensing rule for mifepristone, rather than rule on it immediately, while FDA's own safety review of the drug's Risk Evaluation and Mitigation Strategy (REMS) proceeds. He gave the government six months — until October 7, 2026 — to file a status report on that review's progress and any updated completion timeframe.

What is FDA actually reviewing?

On September 19, 2025, HHS Secretary Robert F. Kennedy Jr. and then-FDA Commissioner Marty Makary announced a study of mifepristone's REMS, including the dispensing restrictions, to determine whether modifications are necessary. The announcement followed a request from attorneys general in 22 states citing studies they said raised new safety concerns; critics, including reproductive-rights groups, have questioned the review's scientific basis and timeline.

What did the judge actually rule in April?

Judge Joseph declined to immediately block the 2023 rule that lets mifepristone be prescribed by telehealth and dispensed by mail, so that access continues for now. But he also found that Louisiana has standing to sue and is likely to succeed on the merits of its claim that FDA's pre-2023 REMS changes were unlawful — meaning the pause is not a win for either side so much as a deferral, with the judge saying explicitly it is not indefinite.

What happens after October 7?

FDA's report will tell the court, and the public, how far along the REMS review actually is and when FDA expects to finish — information that has not previously been made public in detail. Depending on what it says, Judge Joseph could extend the pause, move to rule on the underlying legal challenge, or take some other case-management step. As of this writing, the report itself had not yet been filed.